Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Lymphodepleting Chemotherapy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 16 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03056339
What this trial is testing

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

Who this might be right for
B-Lymphoid MalignanciesAcute Lymphocytic LeukemiaChronic Lymphocytic Leukemia+1 more
M.D. Anderson Cancer Center 49
Early research (Phase 1)Looking for participantsNCT06072989
What this trial is testing

Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid Tumors

Who this might be right for
Advanced Solid Tumor
Shanghai East Hospital 24
Early research (Phase 1)Temporarily pausedNCT03710421
What this trial is testing

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
City of Hope Medical Center 30
Testing effectiveness (Phase 2)Study completedNCT00328861
What this trial is testing

Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer

Who this might be right for
Metastatic MelanomaMetastatic Kidney Cancer
National Cancer Institute (NCI) 8
Early research (Phase 1)Looking for participantsNCT06340737
What this trial is testing

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Who this might be right for
Follicular LymphomaMantle Cell LymphomaHairy Cell Leukemia+5 more
Stanford University 148
Early research (Phase 1)Looking for participantsNCT06083883
What this trial is testing

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

Who this might be right for
Synovial SarcomaMyxoid/Round Cell Liposarcoma
M.D. Anderson Cancer Center 44
Early research (Phase 1)Looking for participantsNCT05052528
What this trial is testing

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
University of California, Davis 36
Testing effectiveness (Phase 2)Looking for participantsNCT06383572
What this trial is testing

Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies

Who this might be right for
Lymphodepleting ChemotherapyMyeloid Malignancies
M.D. Anderson Cancer Center 44
Testing effectiveness (Phase 2)Ended earlyNCT00138229
What this trial is testing

Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma

Who this might be right for
Melanoma (Skin)
National Institutes of Health Clinical Center (CC) 6
Early research (Phase 1)Study completedNCT05628883
What this trial is testing

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Who this might be right for
Metastatic MelanomaUnresectable MelanomaAcral Melanoma+7 more
H. Lee Moffitt Cancer Center and Research Institute 17
Testing effectiveness (Phase 2)Study completedNCT01105650
What this trial is testing

Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer+1 more
Masonic Cancer Center, University of Minnesota 13
Testing effectiveness (Phase 2)Looking for participantsNCT07589543
What this trial is testing

Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer

Who this might be right for
Epithelial Ovarian CancerEpithelial Ovarian Cancer, Fallopian Tube or Peritoneum
Beijing Biotech 42
Testing effectiveness (Phase 2)Looking for participantsNCT05092451
What this trial is testing

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Who this might be right for
B-Cell LymphomaMyelodysplastic Syndromes (MDS)Acute Myeloid Leukemia (AML)+7 more
M.D. Anderson Cancer Center 80
Testing effectiveness (Phase 2)Looking for participantsNCT07589530
What this trial is testing

Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors

Who this might be right for
Advanced Solid TumorsMetastatic Solid TumorsTROP2-Expressing Solid Tumors
Beijing Biotech 60
Testing effectiveness (Phase 2)Looking for participantsNCT06847269
What this trial is testing

CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia

Who this might be right for
Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital 25
Early research (Phase 1)Looking for participantsNCT06699771
What this trial is testing

Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

Who this might be right for
Lymphoma, T-Cell
GC Cell Corporation 53